J&J Phase 1b/2 OrigAMI-4: Subcutaneous Amivantamab Shows 42% ORR In Head & Neck Cancer
31/5 15:37
(RTTNews) - Johnson & Johnson (JNJ) announced pivotal results from the Phase 1b/2 OrigAMI-4 study, which evaluated subcutaneous amivantamab with hyaluronidase-lpuj in patients with advanced head and neck squamous cell carcinoma previously treated with immunotherapy and chemothera...